Divi's Laboratories Limited is in the process of entering into a long-term supply agreement with a customer and is planning for capacity addition at its manufacturing facility with an estimated investment between Rs. 650 crores to Rs. 700 crores, to be funded from internal accruals.
Laurus Labs Ltd has reported Consolidated financial results for the period ended March 31, 2024.
The pharmaceutical sector led the pack - edging out financial services - in employing women in key managerial personnel (KMP) roles across the top 200 BSE-listed companies.
Mumbai: US private equity fund Advent International is among investors in discussions to acquire a minority stake in Apollo 24/7, the digital healthcare platform of Apollo Hospitals, said two people aware of the development
To create awareness and enable knowledge-sharing around Venous diseases, in order to drive better patient care, BD (Becton, Dickinson, and Company) conducted roadshows across New Delhi, Mumbai and Bangalore recently. Venous disease is a condition where the veins in the body have difficulty returning blood to the heart, thereby resulting in blood clot forming in a vein, typically in the legs. If left untreated, these clots can break loose and travel to the lungs, causing serious complications. Delayed detection and intervention can lead to worsened clinical outcomes and a multitude of problems for both patients and healthcare professionals.
Global pharma major Lupin Limited (Lupin) announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (FDA) for its Aurangabad manufacturing facility. The inspection was conducted from March 6 to March 15, 2024. The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI).
Syngene International Limited has reported Consolidated financial results for the period ended March 31, 2024.
Expansion plans include a new facility, Enmetazobactam launch, and mergers for sustainable growth and reduced import reliance. Orchid Pharma, which is seeing a turnaround under its new promoter Dhanuka Group, aspires to be a fully integrated powerhouse of cephalosporin antibiotics, the company's top executive said
Nestle India profit beats estimates on strong demand; forms JV with Dr. Reddy's